MT-II was designed and characterised through the systematic melanocortin peptide structure-activity relationship programme in Victor Hrubys laboratory at the University of Arizona , the same programme that produced MT-1 , with the cyclisation strategy introduced to further constrain the pharmacophore into a receptor-binding conformation that simultaneously increases potency, metabolic stability, and the receptor subtype selectivity profile that distinguishes MT-II from the linear tridecapeptide MT-1
J Clin Invest,1990
If a patient has vomiting, poor fluid intake, kidney disease, or is taking medicines such as diuretics, ACE inhibitors, ARBs, NSAIDs, or certain kidney-related medicines, dehydration can become more serious
Conceio EM, Mitchell JE, Machado PPP, Vaz AR, Pinto-Bastos A, Ramalho S, et al